WARF: P01006US

Method of Increasing Longevity and Preventing Body Weight Wasting in Autoimmune Disease by Using CLA


Michael Pariza, Mark Cook, Mingder Yang

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method of treating an autoimmune disease by administering CLA.
OVERVIEWLupus is a common autoimmune disease characterized by inflammation of various parts of the body like the skin, blood, and kidneys. Between 500,000 and 1.5 million Americans are afflicted with lupus.
THE INVENTIONUW-Madison researchers have developed a method of treating an autoimmune complex disease by administering an amount of conjugated linoleic acid (CLA). Administering CLA is believed to be effective because CLA can affect the production of prostaglandins and leukotrienes in humans and animals. This in turn reduces the formation of damaging immune complexes and cellular infiltrates.
  • Treating systemic lupus erythematosus, arthritis, multiple sclerosis, Addison’s disease, spontaneous infertility, insulin-dependent diabetes and Graves’ disease
  • Preventing body weight wasting in humans and animals with an advanced stage of autoimmune disease
  • Lessening the symptoms of autoimmune diseases
  • Treating conditions related to nephritis and kidney tissue inflammation associated with various conditions (including autoimmune conditions)
  • Capable of extending the survival time of animals (including humans) with autoimmune complex diseases
  • Prolongs healthy tissue and organ function
For More Information About the Inventors
Contact Information
For current licensing status, please contact Emily Bauer at or 608-960-9842.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.